Skip to content

A clinical study to assess the effect of yoga practice along with conventional treatment in clinical and psychosocial parameters among adults in the age group of 20-60 years with Auto immune Myasthenia Gravis

The effectiveness of modified yoga techniques in improving clinical and psychosocial parameters among adults with Autoimmune Myasthenia Gravis A Randomized Controlled Trial - Nil

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/11/077485
Enrollment
70
Registered
2024-11-29
Start date
Unknown
Completion date
Unknown
Last updated
2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G700- Myasthenia gravis

Interventions

None listed

Sponsors

Renjumol VS
Lead Sponsor
Dr Sruthi S Nair
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient with class II MG, II a MG, II b MG, III MG, III a MG, III b MG, IV MG, IV a MG, clinical classification of the Myasthenia Gravis Foundation of America (MGFA) 2. Patient with mild and moderate QMG score 3. MG-ADL more than 2score 4. Myasthenia Gravis patient complaints with Fatigue 5. Subject within the age group 20 to 60 years in both sex 6. Patients willing for regular follow up and evaluation during the period of study 7. Dose of immunotherapy stable in last 2 months prior to recruitment

Exclusion criteria

Exclusion criteria: 1. Pregnant woman and lactating mother 2. Patients having malignancy, severe systemic illness, COPD 3. Patient unable to perform yoga postures from minimum required yoga procedure 4. Patients who are not giving consent

Design outcomes

Primary

MeasureTime frame
1. The Quality of Life of patients with Autoimmune Myasthenia Gravis measured by Myasthenia Gravis Quality of Life 15 (MG-QoL15) scale 2. Fatigue of patients with Autoimmune Myasthenia Gravis measured by Fatigue Severity Scale (FSS)Timepoint: Study Duration 4 years. Assessment will be done on 0th and 91st day of the study.

Secondary

MeasureTime frame
The anxiety and depression of patients with Autoimmune Myasthenia Gravis measured by HADS scale and stress by Perceived stress scaleTimepoint: Assessment will be done on 0th day, 45th day and 91st day of the study. ;Sleep apnea in patients with Autoimmune Myasthenia Gravis measured by STOP-BANG Sleep Apnea QuestionnaireTimepoint: 0th and 91st day of the study;Activities of Daily Living (MG-ADL), MG QMG score, Myasthenia Gravis Composite (MGC)Timepoint: 0th and 91st of the study;Relapse rate, Frequency of infection and Reducing steroid doses in these subjects by standard questionnaire in patients with Autoimmune Myasthenia GravisTimepoint: 0th 45th and 91st day of the study

Countries

India

Contacts

Public ContactRenjumol VS

vaidyaratnam ayurveda college Trissur

doctorviswagiri@gmail.com9605659777

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026